Noerr advises Laureus Capital on Series B funding for biotech company Ethris

A multidisciplinary team from Noerr under the remit of our Berlin partner Dominik Rompza has advised Laureus Capital GmbH, the investment company of Goodgames founders Christian Wawrzinek and Kai Wawrzinek based in Hamburg. Laureus is acquiring an interest in Munich-based biotechnology company Ethris as part of a Series B funding round worth $26.3 million.

Noerr advised Laureus on the legal and tax aspects of the transaction and carried out a financial due diligence.

Christian Wawrzinek will be supporting Ethris as its managing director and chief corporate strategy officer in the future.

Ethris, a biotech company based in Planegg near Munich, develops messenger RNA therapeutics. These contain the genetic code as a blueprint for proteins and can therefore be used wherever a missing or defective protein triggers a disease or, more generally, where a protein may have therapeutic value.

Advisors to Laureus Capital GmbH: Noerr Partnerschaftsgesellschaft mbB

Lead: Dominik Rompza (partner, Private Equity, Berlin)

Private Equity/Corporate/M&A
Christian Pleister (partner), Daniel Fuchs, Jin-Sa John Jun (associates, Berlin)
Florian Becker (partner, Munich)

Intellectual Property
Sebastian Wündisch (partner, Dresden), Natalie Oei (legal advisor, Munich)

Regulatory & Governmental Affairs/Gene Technology
Isabel Jakobs (associated partner, Munich)

Employment & Pensions
Stefan Schwab (partner), Mario Merget (senior associate, Berlin)

Insurance
Helmut Katschthaler (partner, Munich)

IT
Torsten Kraul (partner), Marvin Bartels (associate, Berlin)

Financial Advisory
Oliver Schließer (partner), Susanne Carolin Sopart (senior associate, Munich)

Tax
Christian Garz (counsel, Berlin)